Freenome has developed a multi-omics platform that is designed to detect cancer at its early stages using a simple blood draw. The company's unique platform employs a proprietary algorithmic method that strives to revolutionize disease management through systematic early detection and intervention of disease screenings. This allows doctors to treat cancer and other diseases while they are still at manageable stages.

Investors Include:

American Cancer Society, CRV, Polaris Partners, RA Capital Management, Pura Vida Investments, HBM Partners, Rock Springs Capital, S28 Capital, dRx Capital Novartis, ArrowMark Partners, AME Cloud Ventures, Roche Venture Fund, ARTIS Ventures, Third Kind Venture Capital, StartX (US), CEC Capital Group, Bedford Bridge, HBM Healthcare Investments, Asset Management Ventures, K50 Ventures, BrightEdge, Perceptive Advisors, Verily Life Sciences, Soleus Capital, Verizon Communications.

Own Freenome stock or options?

Get an instant valuation

Completely free
100% confidential & secure
Takes less than a minute

What company do you own stock or options in?

How many shares or options do you own?

100% private & secure

Our available services for this company

Lifetime IncomeCharitable Remainder Trust

Tax SavingsDonor Advised Fund